AR040922A1 - Composicion inmunogenica multivalente, uso de la misma para la fabricacion de un medicamento y procedimiento para preparar dicha composicion inmunogenica multivalente - Google Patents
Composicion inmunogenica multivalente, uso de la misma para la fabricacion de un medicamento y procedimiento para preparar dicha composicion inmunogenica multivalenteInfo
- Publication number
- AR040922A1 AR040922A1 ARP010103098A ARP010103098A AR040922A1 AR 040922 A1 AR040922 A1 AR 040922A1 AR P010103098 A ARP010103098 A AR P010103098A AR P010103098 A ARP010103098 A AR P010103098A AR 040922 A1 AR040922 A1 AR 040922A1
- Authority
- AR
- Argentina
- Prior art keywords
- capsular polysaccharide
- serotype
- streptococcus pneumoniae
- polysaccharide
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 230000002163 immunogen Effects 0.000 title abstract 8
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000004676 glycans Chemical class 0.000 abstract 41
- 229920001282 polysaccharide Polymers 0.000 abstract 40
- 239000005017 polysaccharide Substances 0.000 abstract 40
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 18
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 18
- 241000606768 Haemophilus influenzae Species 0.000 abstract 8
- 239000002775 capsule Substances 0.000 abstract 8
- 201000009906 Meningitis Diseases 0.000 abstract 6
- 230000001580 bacterial effect Effects 0.000 abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 abstract 3
- 108010078791 Carrier Proteins Proteins 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract 2
- 241000194017 Streptococcus Species 0.000 abstract 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052782 aluminium Inorganic materials 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 abstract 1
- 102000016607 Diphtheria Toxin Human genes 0.000 abstract 1
- 108010053187 Diphtheria Toxin Proteins 0.000 abstract 1
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 abstract 1
- 241000588655 Moraxella catarrhalis Species 0.000 abstract 1
- 101710183389 Pneumolysin Proteins 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 101710188053 Protein D Proteins 0.000 abstract 1
- 101710132893 Resolvase Proteins 0.000 abstract 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 abstract 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000004804 polysaccharides Polymers 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición inmunogénica multivalente que comprende un conjugado de una proteína vehículo y el polisacárido capsular de H. influenzae de tipo B, comprendiendo adicionalmente la citada composición 2 ó más polisacáridos bacterianos adicionales capaces de conferir a un huésped frente a una infección por las bacterias de las que derivan, y en la que el conjugado de polisacárido capsular de H. influenzae de tipo B no está absorbida sobre una sal coadyuvante de aluminio. La composición inmunogénica multivalente puede comprender más de 7 polisacáridos bacterianos adicionales, por ejemplo del tipo neumocócicos. Preferentemente, ninguno de los polisacáridos de la composición está absorbido sobre sal coadyuvante de aluminio. Los polisacáridos bacterianos adicionales pueden seleccionarse de un grupo constituido por polisacárido capsular de serogrupo A de N. meningitis, polisacárido capsular de serogrupo C de N. meningitis, polisacárido capsular de serogrupo Y de N. meningitis, polisacárido capsular de serogrupo W de N. meningitis, polisacárido capsular de serotipo 1 de Streptococcus pneumoniae, polisacárido capsular de serotipo 3 de Streptococcus pneumoniae, polisacárido capsular de serotipo 4 de Streptococcus pneumoniae, polisacárido capsular de serotipo 5 de Streptococcus pneumoniae, polisacárido capsular de serotipo 6A de Streptococcus pneumoniae, polisacárido capsular de serotipo 6B de Streptococcus pneumoniae, polisacárido capsular de serotipo 7F de Streptococcus pneumoniae, polisacárido capsular de serotipo 8 de Streptococcus pneumoniae, polisacárido capsular de serotipo 9N de Streptococcus pneumoniae, polisacárido capsular de serotipo 9V de Streptococcus pneumoniae, polisacárido capsular de serotipo 10A de Streptococcus pneumoniae, polisacárido capsular de serotipo 11A de Streptococcus pneumoniae, polisacárido capsular de serotipo 12F de Streptococcus pneumoniae, polisacárido capsular de serotipo 14 de Streptococcus pneumoniae, polisacárido capsular de serotipo 15B de Streptococcus pneumoniae, polisacárido capsular de serotipo 17F de Streptococcus pneumoniae, polisacárido capsular de serotipo 18C de Streptococcus pneumoniae, polisacárido capsular de serotipo 19A de Streptococcus pneumoniae, polisacárido capsular de serotipo 19F de Streptococcus pneumoniae, polisacárido capsular de serotipo 20 de Streptococcus pneumoniae, polisacárido capsular de serotipo 22F de Streptococcus pneumoniae, polisacárido capsular de serotipo 23F de Streptococcus pneumoniae, polisacárido capsular de serotipo33F de Streptococcus pneumoniae, polisacárido capsular de grupo I de Streptococcus de grupo B, polisacárido capsular de grupo II de Streptococcus de grupo B, polisacárido capsular de grupo III de Streptococcus de grupo B, polisacárido capsular de grupo IV de Streptococcus de grupo B, polisacárido capsular de grupo V de Streptococcus de grupo B, polisacárido capsular de tipo 5 de Staphylococcus aureus, polisacárido capsular de tipo 8 de Staphylococcus aureus, polisacárido Vi de Salmonella typhi. LPS. de N. meningitis, LPS de M. catarrhalis y LPS de H. Influenzae. Los polisacáridos bacterianos adicionales pueden estar conjugados con una proteína vehículo. Dicha proteína vehículo utilizable puede seleccionarse del grupo que comprende: toxoide del tétanos, toxoide de la difteria, CRM197, toxina de la difteria recombinante, OMPC de N. meningitis, pneumolisina de S. Pneumoniae y proteína D de H. influenzae. Preferentemente, el polisacárido capsular de H. influenzae de tipo B y los polisacáridos adicionales no están conjugados con el mismo vehículo. En forma más preferente aún, el polisacárido capsular de H. influenzae de tipo y los polisacáridos adicionales no están conjugados todos con CRM197. Uso de la composición inmunogénica multivalente para la fabricación de un medicamento de aplicación en el tratamiento o la prevención de enfremedades causadas por Haemophilus influenzae. Uso de la composición inmunogénica multivalente para la fabricación de un medicamento de aplicación en un procedimiento, dicho tratamiento de inmunización de un huésped humano frente a una enfermedad causada por Haemophilus influenzae, comprende administrar al huésped una dosis inmunoprotrectora de la composición inmunogénica multivalente descripta. Un procesamiento para preparar la composición inmunogénica multivalente que comprende la etapa de mezclar conjuntamente los componentes individuales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0108364.1A GB0108364D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040922A1 true AR040922A1 (es) | 2005-04-27 |
Family
ID=9912183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103098A AR040922A1 (es) | 2001-04-03 | 2001-06-28 | Composicion inmunogenica multivalente, uso de la misma para la fabricacion de un medicamento y procedimiento para preparar dicha composicion inmunogenica multivalente |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20040202668A1 (es) |
| EP (4) | EP1390066B1 (es) |
| JP (3) | JP5281224B2 (es) |
| KR (7) | KR101045412B1 (es) |
| CN (3) | CN1273190C (es) |
| AR (1) | AR040922A1 (es) |
| AT (2) | ATE553776T1 (es) |
| BR (1) | BR0208595A (es) |
| CA (3) | CA2442865C (es) |
| CY (3) | CY1112880T1 (es) |
| CZ (1) | CZ20032698A3 (es) |
| DK (3) | DK1946771T3 (es) |
| ES (3) | ES2384041T3 (es) |
| GB (1) | GB0108364D0 (es) |
| HK (3) | HK1114781A1 (es) |
| HU (1) | HUP0303996A3 (es) |
| IL (2) | IL158066A0 (es) |
| MX (1) | MXPA03008961A (es) |
| MY (1) | MY129263A (es) |
| NO (1) | NO20034410L (es) |
| NZ (3) | NZ581373A (es) |
| PL (5) | PL211911B1 (es) |
| PT (3) | PT1946771E (es) |
| SI (3) | SI1390066T1 (es) |
| WO (1) | WO2002080965A2 (es) |
| ZA (1) | ZA200307640B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| SK288007B6 (sk) * | 2000-06-29 | 2012-10-02 | Glaxosmithkline Biologicals S. A. | Multivalent vaccine composition, process for its producing, and its use |
| US7527797B1 (en) * | 2000-09-01 | 2009-05-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vibrio cholerae 0139 conjugate vaccines |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| JP2007516219A (ja) | 2003-05-07 | 2007-06-21 | アヴェンティス パストゥール インコーポレイテッド | 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法 |
| CA2530434A1 (en) * | 2003-06-23 | 2005-01-06 | Aventis Pasteur, Inc. | Immunization method against neisseria meningitidis serogroups a and c |
| CN103405761A (zh) | 2003-10-02 | 2013-11-27 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
| EP2272531A3 (en) | 2004-04-30 | 2011-04-13 | Novartis Vaccines and Diagnostics S.r.l. | Integration of meningococcal conjugate vaccination |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0409795D0 (en) * | 2004-04-30 | 2004-06-09 | Glaxosmithkline Biolog Sa | Drying method |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CN102716480B (zh) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| US9931397B2 (en) | 2005-06-27 | 2018-04-03 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| JP5135220B2 (ja) * | 2005-09-01 | 2013-02-06 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 血清群ｃ髄膜炎菌を含む複数ワクチン接種 |
| GB0522303D0 (en) * | 2005-11-01 | 2005-12-07 | Chiron Srl | Culture method |
| US7740855B2 (en) * | 2005-11-30 | 2010-06-22 | Yeda Research & Development Co. Ltd | Inactivated CD8+ T-cells for the treatment of HIV infection |
| AU2012216698B2 (en) * | 2005-12-22 | 2014-03-06 | Glaxosmithkline Biologicals Sa | Pneumococcal polysaccharide conjugate vaccine |
| GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| CN101378778B (zh) | 2005-12-22 | 2013-02-06 | 葛兰素史密丝克莱恩生物有限公司 | 肺炎球菌多糖缀合物疫苗 |
| CA2633789A1 (en) * | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
| US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| PT2004225E (pt) | 2006-03-22 | 2012-05-30 | Novartis Ag | Regimes para imunização com conjugados meningocócicos |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| PT2097102E (pt) | 2006-09-07 | 2012-08-03 | Glaxosmithkline Biolog Sa | Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus |
| US20100074918A1 (en) * | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
| AU2008267208B2 (en) | 2007-06-26 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| CN101559223B (zh) * | 2008-04-18 | 2013-02-13 | 重庆智仁生物技术有限公司 | 流脑白百破联合疫苗 |
| WO2009147980A1 (ja) | 2008-06-04 | 2009-12-10 | 財団法人化学及血清療法研究所 | 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法 |
| AU2009268937A1 (en) * | 2008-06-16 | 2010-01-14 | Aj Park | Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| TWI583393B (zh) * | 2009-06-16 | 2017-05-21 | 中央研究院 | 免疫原性組合物、包含其之疫苗與治療劑及其用途 |
| BR112012004806B8 (pt) | 2009-09-02 | 2022-10-04 | Novartis Ag | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso |
| US20110293700A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| SI3170508T1 (sl) | 2010-06-04 | 2020-01-31 | Wyeth Llc | Formulacije cepiva |
| AU2011295853A1 (en) | 2010-09-01 | 2013-04-04 | Irm Llc | Adsorption of immunopotentiators to insoluble metal salts |
| US20130259948A1 (en) | 2010-09-21 | 2013-10-03 | National Institute Of Immunology | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
| CN102068690A (zh) * | 2010-12-31 | 2011-05-25 | 北京民海生物科技有限公司 | 多价肺炎球菌荚膜多糖结合疫苗及其制备方法 |
| WO2012106251A2 (en) * | 2011-01-31 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pertussis vaccine |
| JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および／またはアジュバントを有する混合ワクチン |
| EP2822584A1 (en) * | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
| CA2866406A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CN103623404B (zh) * | 2012-08-28 | 2016-08-03 | 天士力制药集团股份有限公司 | 一种b型流感嗜血杆菌多糖结合疫苗的制备方法 |
| CN103656631B (zh) * | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法 |
| CA2896552A1 (en) * | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic compositions |
| CN102876707B (zh) * | 2012-10-15 | 2014-05-28 | 北京工业大学 | 一种重组脊髓灰质炎病毒ⅰ型病毒样颗粒的制备方法 |
| KR20150058571A (ko) * | 2012-10-17 | 2015-05-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| US20140193451A1 (en) * | 2012-10-17 | 2014-07-10 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| KR20140075196A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| HRP20221438T1 (hr) | 2012-12-20 | 2023-02-03 | Pfizer Inc. | Postupak glikokonjugiranja |
| CN104069488A (zh) * | 2013-03-29 | 2014-10-01 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
| US11708411B2 (en) * | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| JP6612260B2 (ja) | 2014-01-21 | 2019-11-27 | ファイザー・インク | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3616716A3 (en) * | 2014-01-21 | 2020-05-06 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN107427568B (zh) * | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
| CN106109486A (zh) * | 2015-07-06 | 2016-11-16 | 北京科兴中维生物技术有限公司 | 一种组合物及其制备方法与应用 |
| PE20240927A1 (es) | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
| CN106039301A (zh) * | 2016-06-30 | 2016-10-26 | 武汉博沃生物科技有限公司 | 肺炎球菌‑b型流感嗜血杆菌‑百白破联合疫苗的制备方法 |
| IL264553B2 (en) | 2016-08-05 | 2023-04-01 | Sanofi Pasteur Inc | A multivalent pneumococcal protein-polysaccharide conjugate preparation |
| TWI789357B (zh) | 2016-08-05 | 2023-01-11 | 南韓商Ｓｋ生物科技股份有限公司 | 多價肺炎球菌多醣-蛋白質共軛物組成物(二) |
| CN106432512B (zh) * | 2016-09-30 | 2022-03-01 | 康希诺生物股份公司 | 一种增强多糖抗原免疫原性蛋白载体及其制备方法与应用 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CA3048981A1 (en) * | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| WO2019075372A1 (en) | 2017-10-13 | 2019-04-18 | The Research Foundation For The State University Of New York | COMPREHENSIVE VACCINE DESIGN AGAINST THE PROGRESSION OF COMMENSITY DISEASES |
| US11123417B2 (en) | 2018-02-05 | 2021-09-21 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA3087572A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| AU2019256218A1 (en) | 2018-04-18 | 2020-12-03 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| WO2020165920A1 (en) * | 2019-02-12 | 2020-08-20 | Biological E Limited | Multivalent vaccine composition |
| CN111000994A (zh) * | 2019-12-26 | 2020-04-14 | 北京科兴中维生物技术有限公司 | 一种液体疫苗组合物及其制备方法与应用 |
| CN116942804A (zh) * | 2022-04-19 | 2023-10-27 | 上海瑞宙生物科技有限公司 | 多价肺炎球菌多糖结合疫苗的成分及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| GB8516442D0 (en) | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| DE69324487T2 (de) | 1992-05-06 | 1999-08-12 | Harvard College | Rezeptorbindende region des diphtherietoxius |
| DE69319728T2 (de) * | 1992-05-23 | 1999-02-04 | Smithkline Beecham Biolog | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
| DK0652758T3 (da) | 1992-06-18 | 2000-05-08 | Harvard College | Diferitoxin-vacciner |
| JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | アジュバント含有ワクチン組成物 |
| DE69323264D1 (de) * | 1992-10-27 | 1999-03-11 | American Cyanamid Co | Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente |
| ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5780606A (en) * | 1995-06-07 | 1998-07-14 | Connaught Laboratories Limited | Neisseria meningitidis capsular polysaccharide conjugates |
| PL184872B1 (pl) | 1995-06-23 | 2003-01-31 | Smithkline Beecham Biolog | Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie |
| SE9601158D0 (sv) * | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
| CA2259415A1 (en) * | 1996-07-02 | 1998-01-08 | Connaught Laboratories Limited | Multivalent dtp-polio vaccines |
| GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| BR9714980A (pt) * | 1997-09-15 | 2001-11-06 | Pasteur Merieux Msd | Vacinas multivalentes |
| GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| JP4846906B2 (ja) * | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| SK288007B6 (sk) * | 2000-06-29 | 2012-10-02 | Glaxosmithkline Biologicals S. A. | Multivalent vaccine composition, process for its producing, and its use |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
-
2001
- 2001-04-03 GB GBGB0108364.1A patent/GB0108364D0/en not_active Ceased
- 2001-06-28 AR ARP010103098A patent/AR040922A1/es not_active Application Discontinuation
-
2002
- 2002-03-28 HU HU0303996A patent/HUP0303996A3/hu unknown
- 2002-03-28 ES ES02735199T patent/ES2384041T3/es not_active Expired - Lifetime
- 2002-03-28 PL PL393585A patent/PL211911B1/pl not_active IP Right Cessation
- 2002-03-28 CN CNB028110919A patent/CN1273190C/zh not_active Expired - Fee Related
- 2002-03-28 KR KR1020097023347A patent/KR101045412B1/ko not_active IP Right Cessation
- 2002-03-28 CN CN2006101074116A patent/CN101112619B/zh not_active Expired - Fee Related
- 2002-03-28 CA CA2442865A patent/CA2442865C/en not_active Expired - Fee Related
- 2002-03-28 WO PCT/EP2002/003573 patent/WO2002080965A2/en active Application Filing
- 2002-03-28 IL IL15806602A patent/IL158066A0/xx unknown
- 2002-03-28 CA CA2727715A patent/CA2727715C/en not_active Expired - Fee Related
- 2002-03-28 KR KR1020117028214A patent/KR20120005534A/ko not_active Application Discontinuation
- 2002-03-28 NZ NZ581373A patent/NZ581373A/en not_active IP Right Cessation
- 2002-03-28 EP EP02735199A patent/EP1390066B1/en not_active Revoked
- 2002-03-28 US US10/473,769 patent/US20040202668A1/en not_active Abandoned
- 2002-03-28 NZ NZ551621A patent/NZ551621A/en not_active IP Right Cessation
- 2002-03-28 SI SI200230987T patent/SI1390066T1/sl unknown
- 2002-03-28 ES ES08153845T patent/ES2388690T3/es not_active Expired - Lifetime
- 2002-03-28 EP EP08153845A patent/EP1946771B1/en not_active Expired - Lifetime
- 2002-03-28 PT PT08153845T patent/PT1946771E/pt unknown
- 2002-03-28 KR KR1020087012215A patent/KR20080048094A/ko not_active Application Discontinuation
- 2002-03-28 PL PL393582A patent/PL211909B1/pl not_active IP Right Cessation
- 2002-03-28 SI SI200230995T patent/SI1946771T1/sl unknown
- 2002-03-28 CA CA2810326A patent/CA2810326A1/en not_active Abandoned
- 2002-03-28 BR BRPI0208595-0A patent/BR0208595A/pt not_active IP Right Cessation
- 2002-03-28 NZ NZ568317A patent/NZ568317A/en not_active IP Right Cessation
- 2002-03-28 JP JP2002579004A patent/JP5281224B2/ja not_active Expired - Fee Related
- 2002-03-28 CN CN2006101074101A patent/CN101112618B/zh not_active Expired - Fee Related
- 2002-03-28 AT AT08153847T patent/ATE553776T1/de active
- 2002-03-28 DK DK08153845.6T patent/DK1946771T3/da active
- 2002-03-28 MX MXPA03008961A patent/MXPA03008961A/es active IP Right Grant
- 2002-03-28 EP EP10179818A patent/EP2311488A3/en not_active Withdrawn
- 2002-03-28 PL PL393618A patent/PL211912B1/pl not_active IP Right Cessation
- 2002-03-28 PL PL374106A patent/PL211958B1/pl not_active IP Right Cessation
- 2002-03-28 CZ CZ20032698A patent/CZ20032698A3/cs unknown
- 2002-03-28 KR KR1020097004040A patent/KR20090026371A/ko not_active Application Discontinuation
- 2002-03-28 KR KR1020117027470A patent/KR101292708B1/ko not_active IP Right Cessation
- 2002-03-28 PT PT08153847T patent/PT1946772E/pt unknown
- 2002-03-28 DK DK08153847.2T patent/DK1946772T3/da active
- 2002-03-28 KR KR1020117004885A patent/KR20110036641A/ko not_active Application Discontinuation
- 2002-03-28 DK DK02735199.8T patent/DK1390066T3/da active
- 2002-03-28 PL PL393583A patent/PL211910B1/pl not_active IP Right Cessation
- 2002-03-28 ES ES08153847T patent/ES2384065T3/es not_active Expired - Lifetime
- 2002-03-28 EP EP08153847A patent/EP1946772B1/en not_active Revoked
- 2002-03-28 KR KR1020037012971A patent/KR100870280B1/ko not_active IP Right Cessation
- 2002-03-28 SI SI200230988T patent/SI1946772T1/sl unknown
- 2002-03-28 PT PT02735199T patent/PT1390066E/pt unknown
- 2002-03-28 AT AT02735199T patent/ATE553775T1/de active
- 2002-04-01 MY MYPI20021176A patent/MY129263A/en unknown
-
2003
- 2003-09-30 ZA ZA2003/07640A patent/ZA200307640B/en unknown
- 2003-10-02 NO NO20034410A patent/NO20034410L/no not_active Application Discontinuation
-
2004
- 2004-08-04 HK HK08109370.3A patent/HK1114781A1/xx not_active IP Right Cessation
- 2004-08-04 HK HK08109366.9A patent/HK1114779A1/xx not_active IP Right Cessation
- 2004-08-04 HK HK04105784.5A patent/HK1062891A1/xx not_active IP Right Cessation
-
2007
- 2007-09-11 US US11/853,108 patent/US20080069835A1/en not_active Abandoned
-
2008
- 2008-12-17 JP JP2008320381A patent/JP5095595B2/ja not_active Expired - Fee Related
-
2011
- 2011-05-09 US US13/103,397 patent/US20110212124A1/en not_active Abandoned
- 2011-12-05 JP JP2011265563A patent/JP5410498B2/ja not_active Expired - Fee Related
-
2012
- 2012-06-27 CY CY20121100573T patent/CY1112880T1/el unknown
- 2012-06-27 CY CY20121100572T patent/CY1112879T1/el unknown
- 2012-08-29 CY CY20121100777T patent/CY1113078T1/el unknown
-
2013
- 2013-06-03 US US13/908,064 patent/US20130266609A1/en not_active Abandoned
- 2013-08-15 IL IL227966A patent/IL227966A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040922A1 (es) | Composicion inmunogenica multivalente, uso de la misma para la fabricacion de un medicamento y procedimiento para preparar dicha composicion inmunogenica multivalente | |
| JP7268125B2 (ja) | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 | |
| JP4870895B2 (ja) | ワクチン組成物 | |
| HRP20110685T1 (hr) | Cjepivo od konjugata pneumokoknog polisaharida | |
| ES2911490T3 (es) | Composiciones inmunogénicas para su uso en vacunas antineumocócicas | |
| AU750913B2 (en) | Vaccine | |
| JP2020514326A (ja) | 肺炎連鎖球菌多糖−タンパク質コンジュゲートの免疫原性の増強 | |
| JP5698770B2 (ja) | 担体タンパク質への細菌多糖のコンジュゲーションプロセス | |
| JP2004501873A5 (es) | ||
| PE20211888A1 (es) | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso | |
| JP2019526621A5 (es) | ||
| RU2007112794A (ru) | Гликозилцерамидный адъювант для сахаридных антигенов | |
| CA2435681A1 (en) | Multivalent meningococcal polysaccharide-protein conjugate vaccine | |
| RU2006114677A (ru) | Жидкие вакцины для множественных серогрупп менингококков | |
| RU2004136299A (ru) | Мукозальные вакцины с хитозановым адъювантом и/или антигенами менингококков | |
| CN102933229A (zh) | 疫苗制剂 | |
| PT1868645E (pt) | Composição conjugada de polissacárido-proteína pneumocócica polivalente | |
| RU2004136295A (ru) | Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку | |
| JP2005508849A5 (es) | ||
| JP2019526620A5 (es) | ||
| CN103402544A (zh) | 缀合方法 | |
| Makela | Conjugate vaccines-a breakthrough in vaccine development | |
| Buttery et al. | Designing meningitis vaccines | |
| Beuvery | Immunisation against bacterial meningitis | |
| MÄKELÄ | New bacterial vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |